Praxis Precision’s Elsunersen Received EMA’s PRIME Designation for SCN2A Developmental and Epileptic Encephalopathy (SCN2A-DEE)
Shots:
- The PRIME designation was based on part 1 of the EMBRAVE study evaluating the safety & tolerability of elsunersen in a cohort study on pediatric patients aged 2 to 18yrs. for 13wks.
- The result of the study demonstrated reduction in seizures & improvement in seizure-free days along with preclinical data. The drug has already received ODD from the FDA & EMA, additionally RPD from the FDA for SCN2A-DEE treatment
- Elsunersen is a type of antisense oligonucleotide (ASO) developed to specifically decrease the expression of the SCN2A gene. The program is currently being carried out in collaboration with Ionis Pharmaceuticals and RogCon
Ref: BioSpace | Image: Praxis Precision
Related News:- The US FDA Approved Recor Medical and Otsuka Medical Devices’ Paradise Ultrasound Renal Denervation System for Hypertension
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
